Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 1/2 1

Status

Completed 3

Sponsor Class

OTHER 6NIH 3INDUSTRY 3OTHER_GOV 1NETWORK 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 88Lymphoid 28Other hematologic neoplasm 18Classical hematology 5Sarcoma 4Myeloid 4Thoracic 3Gynecologic 3Gastrointestinal 3Genitourinary 2Dermatologic 2Breast 2Other 1Head & Neck 1

Conditions

Carcinoma, Non-Small-Cell Lung 2729Lung Neoplasms 945Small Cell Lung Carcinoma 447Neoplasms 419Colorectal Neoplasms 409Breast Neoplasms 355Melanoma 332Ovarian Neoplasms 316Neoplasm Metastasis 281Pancreatic Neoplasms 252Squamous Cell Carcinoma of Head and Neck 232Stomach Neoplasms 227Carcinoma, Renal Cell 214Triple Negative Breast Neoplasms 190Head and Neck Neoplasms 178Prostatic Neoplasms 152Esophageal Neoplasms 149Endometrial Neoplasms 145Uterine Cervical Neoplasms 139Urinary Bladder Neoplasms 132Mesothelioma 115Carcinoma 106Colonic Neoplasms 104Carcinoma, Hepatocellular 104Sarcoma 99Carcinoma, Transitional Cell 99Kidney Neoplasms 74Mesothelioma, Malignant 72Cholangiocarcinoma 67Liver Neoplasms 66

Interventions

saracatinib 1resiquimod 1poly ICLC 1pembrolizumab 1cediranib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
INDUSTRY × Neoplasms, Plasma Cell × Thoracic × Clear all
NCT04354246 2026-05-12

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

Compugen Ltd

Phase 1 Completed
94 enrolled
GastrointestinalGynecologicHead & NeckPlasma cellThoracic

Squamous Cell Carcinoma of Head and Neck, Colonic Neoplasms, Lung Neoplasms, Multiple Myeloma, Ovarian Neoplasms, Neoplasms, Plasma Cell

NCT00948961 2016-06-27

A Study of CDX-1401 in Patients With Malignancies Known to Express NY-ESO-1

Celldex Therapeutics

Phase 1/2 Completed
70 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicPlasma cellSarcomaThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Esophageal Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Neoplasms, Plasma Cell

NCT00475956 2010-04-15

Safety and Tolerability Study of AZD2171 in Combination With AZD0530 in Patients With Advanced Solid Tumours

AstraZeneca

Phase 1 Completed
40 enrolled
BreastGastrointestinalGynecologicPlasma cellThoracic

Breast Neoplasms, Choriocarcinoma, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Cholangiocarcinoma, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡